Predicting the risk of hyperkalemia in patients with chronic kidney disease starting lisinopril

Eric S. Johnson, Jessica R. Weinstein, Micah L. Thorp, Robert W. Platt, Amanda F. Petrik, Xiuhai Yang, Sharon Anderson, David H. Smith

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Purpose: Angiotensin-converting enzyme (ACE) inhibitors are recommended for patients with chronic kidney disease (CKD) because they slow disease progression. But physicians' concerns about the risk of hyperkalemia (elevated serum potassium level), a potentially fatal adverse effect, may limit optimal management with ACE-inhibitors.We synthesized known predictors of hyperkalemia into a prognostic risk score to predict the risk of hyperkalemia. Methods: We assembled a retrospective cohort of adult patients with possible CKD (at least one estimated glomerular filtration rate (eGFR) value less than 60 ml/min/1.73m2) who started an ACE-inhibitor (i.e., incident users) between 1998 and 2006 at a health maintenance organization. We followed patients for hyperkalemia: (1) potassium value >5.5 mmol/L; or (2) diagnosis code for hyperkalemia. Cox regression synthesized a priori predictors recorded in the electronic medical record into a risk score. Results: We followed 5171 patients and 145 experienced hyperkalemia, a 90-day risk of 2.8%. Predictors included: age, eGFR, diabetes, heart failure, potassium supplements, potassium-sparing diuretics, and a high dose for the ACE-inhibitor (lisinopril). The risk score separated high-risk patients (top quintile, observed risk of 6.9%) from low-risk patients (bottom quintile, observed risk of 0.7%). Predicted and observed risks agreed within 1% for each quintile. The risk increased gradually in relation to declining eGFR with no apparent threshold for contraindicating ACE-inhibitors. Conclusions: The risk score separated high-risk patients (who may need more intensive laboratory monitoring) from low-risk patients. The risk score should be validated in other populations before it is ready for use in clinical practice.

Original languageEnglish (US)
Pages (from-to)266-272
Number of pages7
JournalPharmacoepidemiology and Drug Safety
Volume19
Issue number3
DOIs
StatePublished - Mar 2010

Fingerprint

Lisinopril
Hyperkalemia
Chronic Renal Insufficiency
Angiotensin-Converting Enzyme Inhibitors
Glomerular Filtration Rate
Potassium
Potassium Sparing Diuretics
Health Maintenance Organizations
Electronic Health Records

Keywords

  • ACE-inhibitors
  • Adverse effects
  • Chronic kidney disease
  • Cohort study
  • Hyperkalemia
  • Risk score

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Epidemiology

Cite this

Johnson, E. S., Weinstein, J. R., Thorp, M. L., Platt, R. W., Petrik, A. F., Yang, X., ... Smith, D. H. (2010). Predicting the risk of hyperkalemia in patients with chronic kidney disease starting lisinopril. Pharmacoepidemiology and Drug Safety, 19(3), 266-272. https://doi.org/10.1002/pds.1923

Predicting the risk of hyperkalemia in patients with chronic kidney disease starting lisinopril. / Johnson, Eric S.; Weinstein, Jessica R.; Thorp, Micah L.; Platt, Robert W.; Petrik, Amanda F.; Yang, Xiuhai; Anderson, Sharon; Smith, David H.

In: Pharmacoepidemiology and Drug Safety, Vol. 19, No. 3, 03.2010, p. 266-272.

Research output: Contribution to journalArticle

Johnson, ES, Weinstein, JR, Thorp, ML, Platt, RW, Petrik, AF, Yang, X, Anderson, S & Smith, DH 2010, 'Predicting the risk of hyperkalemia in patients with chronic kidney disease starting lisinopril', Pharmacoepidemiology and Drug Safety, vol. 19, no. 3, pp. 266-272. https://doi.org/10.1002/pds.1923
Johnson, Eric S. ; Weinstein, Jessica R. ; Thorp, Micah L. ; Platt, Robert W. ; Petrik, Amanda F. ; Yang, Xiuhai ; Anderson, Sharon ; Smith, David H. / Predicting the risk of hyperkalemia in patients with chronic kidney disease starting lisinopril. In: Pharmacoepidemiology and Drug Safety. 2010 ; Vol. 19, No. 3. pp. 266-272.
@article{8e0c7adfde3a41059d602dc1e8cf28c1,
title = "Predicting the risk of hyperkalemia in patients with chronic kidney disease starting lisinopril",
abstract = "Purpose: Angiotensin-converting enzyme (ACE) inhibitors are recommended for patients with chronic kidney disease (CKD) because they slow disease progression. But physicians' concerns about the risk of hyperkalemia (elevated serum potassium level), a potentially fatal adverse effect, may limit optimal management with ACE-inhibitors.We synthesized known predictors of hyperkalemia into a prognostic risk score to predict the risk of hyperkalemia. Methods: We assembled a retrospective cohort of adult patients with possible CKD (at least one estimated glomerular filtration rate (eGFR) value less than 60 ml/min/1.73m2) who started an ACE-inhibitor (i.e., incident users) between 1998 and 2006 at a health maintenance organization. We followed patients for hyperkalemia: (1) potassium value >5.5 mmol/L; or (2) diagnosis code for hyperkalemia. Cox regression synthesized a priori predictors recorded in the electronic medical record into a risk score. Results: We followed 5171 patients and 145 experienced hyperkalemia, a 90-day risk of 2.8{\%}. Predictors included: age, eGFR, diabetes, heart failure, potassium supplements, potassium-sparing diuretics, and a high dose for the ACE-inhibitor (lisinopril). The risk score separated high-risk patients (top quintile, observed risk of 6.9{\%}) from low-risk patients (bottom quintile, observed risk of 0.7{\%}). Predicted and observed risks agreed within 1{\%} for each quintile. The risk increased gradually in relation to declining eGFR with no apparent threshold for contraindicating ACE-inhibitors. Conclusions: The risk score separated high-risk patients (who may need more intensive laboratory monitoring) from low-risk patients. The risk score should be validated in other populations before it is ready for use in clinical practice.",
keywords = "ACE-inhibitors, Adverse effects, Chronic kidney disease, Cohort study, Hyperkalemia, Risk score",
author = "Johnson, {Eric S.} and Weinstein, {Jessica R.} and Thorp, {Micah L.} and Platt, {Robert W.} and Petrik, {Amanda F.} and Xiuhai Yang and Sharon Anderson and Smith, {David H.}",
year = "2010",
month = "3",
doi = "10.1002/pds.1923",
language = "English (US)",
volume = "19",
pages = "266--272",
journal = "Pharmacoepidemiology and Drug Safety",
issn = "1053-8569",
publisher = "John Wiley and Sons Ltd",
number = "3",

}

TY - JOUR

T1 - Predicting the risk of hyperkalemia in patients with chronic kidney disease starting lisinopril

AU - Johnson, Eric S.

AU - Weinstein, Jessica R.

AU - Thorp, Micah L.

AU - Platt, Robert W.

AU - Petrik, Amanda F.

AU - Yang, Xiuhai

AU - Anderson, Sharon

AU - Smith, David H.

PY - 2010/3

Y1 - 2010/3

N2 - Purpose: Angiotensin-converting enzyme (ACE) inhibitors are recommended for patients with chronic kidney disease (CKD) because they slow disease progression. But physicians' concerns about the risk of hyperkalemia (elevated serum potassium level), a potentially fatal adverse effect, may limit optimal management with ACE-inhibitors.We synthesized known predictors of hyperkalemia into a prognostic risk score to predict the risk of hyperkalemia. Methods: We assembled a retrospective cohort of adult patients with possible CKD (at least one estimated glomerular filtration rate (eGFR) value less than 60 ml/min/1.73m2) who started an ACE-inhibitor (i.e., incident users) between 1998 and 2006 at a health maintenance organization. We followed patients for hyperkalemia: (1) potassium value >5.5 mmol/L; or (2) diagnosis code for hyperkalemia. Cox regression synthesized a priori predictors recorded in the electronic medical record into a risk score. Results: We followed 5171 patients and 145 experienced hyperkalemia, a 90-day risk of 2.8%. Predictors included: age, eGFR, diabetes, heart failure, potassium supplements, potassium-sparing diuretics, and a high dose for the ACE-inhibitor (lisinopril). The risk score separated high-risk patients (top quintile, observed risk of 6.9%) from low-risk patients (bottom quintile, observed risk of 0.7%). Predicted and observed risks agreed within 1% for each quintile. The risk increased gradually in relation to declining eGFR with no apparent threshold for contraindicating ACE-inhibitors. Conclusions: The risk score separated high-risk patients (who may need more intensive laboratory monitoring) from low-risk patients. The risk score should be validated in other populations before it is ready for use in clinical practice.

AB - Purpose: Angiotensin-converting enzyme (ACE) inhibitors are recommended for patients with chronic kidney disease (CKD) because they slow disease progression. But physicians' concerns about the risk of hyperkalemia (elevated serum potassium level), a potentially fatal adverse effect, may limit optimal management with ACE-inhibitors.We synthesized known predictors of hyperkalemia into a prognostic risk score to predict the risk of hyperkalemia. Methods: We assembled a retrospective cohort of adult patients with possible CKD (at least one estimated glomerular filtration rate (eGFR) value less than 60 ml/min/1.73m2) who started an ACE-inhibitor (i.e., incident users) between 1998 and 2006 at a health maintenance organization. We followed patients for hyperkalemia: (1) potassium value >5.5 mmol/L; or (2) diagnosis code for hyperkalemia. Cox regression synthesized a priori predictors recorded in the electronic medical record into a risk score. Results: We followed 5171 patients and 145 experienced hyperkalemia, a 90-day risk of 2.8%. Predictors included: age, eGFR, diabetes, heart failure, potassium supplements, potassium-sparing diuretics, and a high dose for the ACE-inhibitor (lisinopril). The risk score separated high-risk patients (top quintile, observed risk of 6.9%) from low-risk patients (bottom quintile, observed risk of 0.7%). Predicted and observed risks agreed within 1% for each quintile. The risk increased gradually in relation to declining eGFR with no apparent threshold for contraindicating ACE-inhibitors. Conclusions: The risk score separated high-risk patients (who may need more intensive laboratory monitoring) from low-risk patients. The risk score should be validated in other populations before it is ready for use in clinical practice.

KW - ACE-inhibitors

KW - Adverse effects

KW - Chronic kidney disease

KW - Cohort study

KW - Hyperkalemia

KW - Risk score

UR - http://www.scopus.com/inward/record.url?scp=77649217394&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77649217394&partnerID=8YFLogxK

U2 - 10.1002/pds.1923

DO - 10.1002/pds.1923

M3 - Article

VL - 19

SP - 266

EP - 272

JO - Pharmacoepidemiology and Drug Safety

JF - Pharmacoepidemiology and Drug Safety

SN - 1053-8569

IS - 3

ER -